- Home
- AKBA vs RLTY Comparison
AKBA vs RLTY Comparison
Compare AKBA & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- RLTY
- Stock Information
- Founded
- AKBA 2007
- RLTY 2022
- Country
- AKBA United States
- RLTY United States
- Employees
- AKBA N/A
- RLTY N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- RLTY Investment Managers
- Sector
- AKBA Health Care
- RLTY Finance
- Exchange
- AKBA Nasdaq
- RLTY Nasdaq
- Market Cap
- AKBA 336.2M
- RLTY 277.8M
- IPO Year
- AKBA 2014
- RLTY N/A
- Fundamental
- Price
- AKBA $1.91
- RLTY $16.50
- Analyst Decision
- AKBA Strong Buy
- RLTY
- Analyst Count
- AKBA 2
- RLTY 0
- Target Price
- AKBA $5.75
- RLTY N/A
- AVG Volume (30 Days)
- AKBA 2.3M
- RLTY 86.7K
- Earning Date
- AKBA 11-07-2024
- RLTY 01-01-0001
- Dividend Yield
- AKBA N/A
- RLTY 9.35%
- EPS Growth
- AKBA N/A
- RLTY N/A
- EPS
- AKBA N/A
- RLTY N/A
- Revenue
- AKBA $169,879,000.00
- RLTY N/A
- Revenue This Year
- AKBA N/A
- RLTY N/A
- Revenue Next Year
- AKBA $3.23
- RLTY N/A
- P/E Ratio
- AKBA N/A
- RLTY N/A
- Revenue Growth
- AKBA N/A
- RLTY N/A
- 52 Week Low
- AKBA $0.80
- RLTY $11.38
- 52 Week High
- AKBA $2.48
- RLTY $14.60
- Technical
- Relative Strength Index (RSI)
- AKBA 68.47
- RLTY 44.53
- Support Level
- AKBA $1.30
- RLTY $15.81
- Resistance Level
- AKBA $2.01
- RLTY $16.52
- Average True Range (ATR)
- AKBA 0.12
- RLTY 0.30
- MACD
- AKBA 0.04
- RLTY -0.06
- Stochastic Oscillator
- AKBA 78.52
- RLTY 36.34
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.